MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$32,800K
EPS
$0.3
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
-
25,031
10,502*
-
Research and development
28,000
25,031
38,287*
44,931
General and administrative
-
6,086
4,785*
-
General and administrative
6,351
6,086
4,785*
4,568
Total operating expenses
-
31,117
15,287
-
Total operating expenses
34,351
31,117
43,072
49,499
Loss from operations
-
-31,117
-15,287*
-
Loss from operations
-34,351
-31,117
-43,072*
-49,499
Other income, net
-
1,504
1,729*
-
Other income, net
1,569
1,504
1,729*
1,787
Net loss
-32,782
-29,613
-13,559*
-47,712
Unrealized loss on marketable securities
-18
-48
-23
-
Net loss
-
-28,225
-41,344*
-
Total other comprehensive loss
-18
-48
-23*
-
Total comprehensive loss
-32,800
-29,661
-54,926
-
Basic EPS
0.3
-0.31
-0.718
-0.61
Diluted EPS
0.3
-0.31
-0.718
-0.61
Basic Average Shares
103,882,937
89,814,820
76,491,122
78,324,767
Diluted Average Shares
103,882,937
89,814,820
76,491,122
78,324,767
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Total comprehensive
loss
-$32,800K
Net loss
-$32,782K
(-25.21%↓ Y/Y)
Total other
comprehensive loss
-$18K
Other income, net
$1,569K
(-2.55%↓ Y/Y)
Loss from operations
-$34,351K
(-23.60%↓ Y/Y)
Unrealized loss on
marketable securities
-$18K
Total operating
expenses
$34,351K
(23.60%↑ Y/Y)
Research and development
$28,000K
(19.82%↑ Y/Y)
General and
administrative
$6,351K
(43.56%↑ Y/Y)
Buy us a coffee
Larimar Therapeutics, Inc. (LRMR)
Larimar Therapeutics, Inc. (LRMR)